Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of ALKS 3831 in Adults With Schizophrenia

This study has been completed.
Information provided by (Responsible Party):
Alkermes, Inc. Identifier:
First received: July 5, 2013
Last updated: April 7, 2015
Last verified: April 2015
This is a Phase 2, randomized, placebo-controlled multicenter study, which will be conducted in 2 parts. The study duration for each subject will be approximately 33 weeks and will include 25 study visits.

Condition Intervention Phase
Drug: Samidorphan (Low Dose)
Drug: Samidorphan (Medium Dose)
Drug: Samidorphan (High Dose)
Drug: Placebo
Drug: Olanzapine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine

Resource links provided by NLM:

Further study details as provided by Alkermes, Inc.:

Primary Outcome Measures:
  • Change in Positive and Negative Syndrome Scale (PANSS) score [ Time Frame: 12 weeks ]
    Change from baseline

Secondary Outcome Measures:
  • Percent change in body weight from baseline to the end of Part A [ Time Frame: 12 weeks ]
  • Safety and tolerability of samidorphan (ALKS 33) [ Time Frame: 29 weeks ]
    Safety and tolerability will be assessed by number and percentage of subjects with adverse events (AEs).

  • Change in body weight [ Time Frame: 12 weeks ]
  • Proportion of subjects exhibiting significant weight gain [ Time Frame: 12 weeks ]
    Significant weight gain will include body weight gain greater than 7%

  • Change in Clinical Global Impressions - Severity (CGI-S) [ Time Frame: 12 weeks ]

Enrollment: 309
Study Start Date: June 2013
Study Completion Date: March 2015
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low Dose
Olanzapine + low dose samidorphan tablets taken once daily
Drug: Samidorphan (Low Dose)
Tablets taken once daily
Other Name: Low dose samidorphan (ALKS 33)
Drug: Olanzapine
Tablets taken once daily
Experimental: Medium Dose
Olanzapine + medium dose samidorphan tablets taken once daily
Drug: Samidorphan (Medium Dose)
Tablets taken once daily
Other Name: Medium dose samidorphan (ALKS 33)
Drug: Olanzapine
Tablets taken once daily
Experimental: High Dose
Olanzapine + high dose samidorphan tablets taken once daily
Drug: Samidorphan (High Dose)
Tablets taken once daily
Other Name: High dose samidorphan (ALKS 33)
Drug: Olanzapine
Tablets taken once daily
Placebo Comparator: Placebo
Olanzapine + placebo tablets taken once daily
Drug: Placebo
Tablets taken once daily
Drug: Olanzapine
Tablets taken once daily


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 to 50 years, inclusive
  • Body mass index (BMI) of 17-30 kg/m2, inclusive
  • Diagnosis of schizophrenia that is clinically stable

Exclusion Criteria:

  • Initiated 1st antipsychotic treatment within the past 12 months and/or has had symptoms lasting <2 years
  • Current diagnosis of alcohol or drug use disorder, moderate or severe
  • Clinically significant or unstable medical illness, condition, or disorder
  • Pregnant or breastfeeding
  • Significant changes in diet or exercise regimen or plans to join a weight management program during the study
  • Opioid medications taken within 14 days and/or need to take opioid medication during the study period
  • History of hypersensitivity to or intolerance of olanzapine
  • Use of olanzapine, clozapine, mesoridazine, chlorpromazine, or thioridazine for more than 1 week during the past year
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01903837

  Show 61 Study Locations
Sponsors and Collaborators
Alkermes, Inc.
Study Director: Bernard L. Silverman, MD Alkermes, Inc.
  More Information

Responsible Party: Alkermes, Inc. Identifier: NCT01903837     History of Changes
Other Study ID Numbers: ALK3831-302
Study First Received: July 5, 2013
Last Updated: April 7, 2015

Keywords provided by Alkermes, Inc.:

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Autonomic Agents
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents processed this record on May 25, 2017